Florida Corrections Commission
1998 Annual Report
5.0. HIV/AIDS in Corrections
5.1. BACKGROUND:
The presence
of HIV (Human Inmmuniodeficiency Virus) and AIDS (Acquired Immune
Deficiency Syndrome) has had a profound effect on the cost of
health care in the correctional setting. The prevalence of
HIV/AIDS in prisons exceeds its prevalence in the general
population. As the prison population increases and inmates are being
incarcerated longer due to stricter sentencing guidelines, the
costs of HIV/AIDS will continue to rise as inmates remain in prison
through the later, more costly stages of the disease and new
treatment protocols are developed. For the past several years,
the Florida Department of Corrections (DC) has reported that
expenditures for the treatment and testing of HIV/AIDS have far
exceeded the appropriation.
This section examines the issue of
HIV/AIDS in corrections and the DC's efforts in dealing with
these diseases. The issues reviewed are: the treatment for
HIV/AIDS; characteristics of inmates with HIV/AIDS; prevalence of
HIV/AIDS in Florida's prisons; HIV testing; housing; correctional
staff; release; HIV transmission in prison; prevention strategies;
costs of testing for and treating HIV/AIDS; and practices in other
correctional systems. (NOTE: Appendix 5.1, is a glossary of HIV/AIDS
related terms found in this section and its appendices.)
5.1.1. Treatment of HIV/AIDS
HIV is transmitted when the blood,
semen, vaginal fluid, or breast milk of an infected person gets into
the body and bloodstream of another person. HIV infection goes
through several stages: acute, chronic, and AIDS, the final stage.
People do not die of AIDS, but rather from complications from the
process of AIDS.1 Appendix 5.2 contains a full
explanation of how HIV causes AIDS and the events in HIV infection.
Combination antiretroviral
therapy is now the standard of care for people with HIV.
The antiretroviral drugs fall into three categories: reverse
transcriptase inhibitors (RTIs, also known as nucleoside analogs),
protease inhibitors, and non-nucleoside reverse transcriptase
inhibitors (NNRTIs). Recent studies show that three-drug
combinations of these antiretroviral drugs are more effective in
preventing disease progression and death than single- or two-drug
therapies. The best combination of antiretroviral treatments to use
is still uncertain and varies from patient to patient. Treatment
regimens are complicated and costly. A typical HIV patient must
take some twenty antiretroviral pills a day, some with meals, some
without. They may also be taking prophylactic medications
(medications taken to prevent other diseases or infections).2
When a patient is in a prison setting, taking the right medication
at the right time can be difficult. HIV can become resistant to the
effects of antiretroviral drugs, making strict adherence to
treatment regimens essential. If a person is noncompliant with
the treatment regimen, they may be considered unsuitable for
treatment.3
When to begin treatment is still
being debated. The viral
load test, which measures the amount of HIV in the blood, along with
the CD4 cell count test can help make that determination. (CD4+
cells normally orchestrate the body's immune responses and are HIV's
preferrred target.) These tests also help to measure the
effectiveness of antiretroviral drug therapy.4
Along with the combination
antiretroviral therapy, persons infected with HIV also require
prophylactic medications to prevent opportunistic infections;
that is, infections that take advantage of compromised immune
systems, some of which are not usually seen in humans. The most
common opportunistic infections associated with HIV/AIDS include
Pneumocystis carinii pneumonia, fungal infections of the mouth,
throat, and intestines, and parasitic eye and brain infections.5
(See Appendix 5.3, Florida Department of Corrections' HIV/AIDS Care
Plan, for the DC's treatment protocol for HIV and opportunistic
infections.)
Although treatment for HIV/AIDS has
improved over the years, there is no cure.
The AIDS Drug Assistance Program
is a federal program that was established in October 1987 to provide
drugs to individuals who otherwise could not afford them.
Each state sets its own criteria for financial and medical
eligibility and the drugs included in the program.6
In Florida, the AIDS Drug
Assistance Program is managed by the Department of Health and funds
are distributed to county health departments.
To be eligible, a patient must have an income at or below 200
percent of the federal poverty level. Patients with incomes between
100-200 percent of federal poverty level are assessed for
co-payments according to a sliding fee scale. Also, their CD4+ cell
count must be less than 500, although this requirement can be
waived. The drugs covered by the program are available through the
Public Health Unit where the client enrolls.7 (Appendix
5.4 lists the drugs included in Florida's AIDS Drug Assistance
Program.)
5.1.2. Inmate Characteristics
The high rates
of HIV/AIDS infection in correctional institutions are related to
behaviors reported by inmates that have been determined to be
high-risk. Not only do inmates engage in more of these
behaviors, they also engage in them more frequently than members of
the general population.8
The number one risk factor for
HIV/AIDS in the correctional setting is injection drug use
prior to incarceration. According to one report, injection drug
users were eight times more likely to test HIV-positive (HIV+) than
a non-drug user entering prison in 1987.9
As one witness testified before the
National Commission on Acquired Immune Deficiency Syndrome, "Because
drug use increases one's risk of incarceration as well as of HIV
infection, the inmate population often constitutes a distillate
of the infection in the community."10
Other at-risk behaviors reported
by inmates include: anal
intercourse; tattooing; a history of multiple sexual partners; a
history of multiple sexually transmitted diseases; poor physical
and/or mental health; and risk-taking personality/behavior.11
Female inmates are more likely
to be infected with HIV/AIDS than male inmates.
This is in contrast to studies that show that males in other
populations have a rate higher than that of females. Women in prison
are more likely to be drug users than are male inmates. Economic
dependency, injection drug use, crack use, and associated increases
in unsafe sexual practices (e.g., exchanging sex for drugs and/or
money) have placed women at elevated risk for HIV infection. A
Massachusetts study found a strong association between sexual abuse
and risk- taking behavior related to HIV. Incarceration rates are
also rising faster among women than men.12
The median racial/ethnic breakdown
of AIDS cases in state/federal systems in 1994 was: 43 percent
black, 38 percent white, and 13 percent Hispanic. This compares
with the distribution among the total cumulative AIDS cases in the
U.S. population: 50 percent white, 32 percent black and 17 percent
Hispanic. A 1991 study found: seroprevalence is greater for male
inmates over 25 years of age and for female inmates under the age of
25; inmates imprisoned for drug and property offenses were more
likely to be infected than violent offenders; and recidivists were
more likely to be HIV+ than first-time admissions.13
5.1.3. Prevalence of HIV/AIDS
in Florida's Prisons
In 1995
Florida ranked seventh nationally, along with Maryland, in
HIV/AIDS cases as a percentage of total custody population (3.4
percent) according to a report by the National Institute of
Justice, up from 2.4 percent in 1991 (ranking ninth). Nationally the
average is 2.3 percent. In 1995 there were 1,971 male cases of HIV,
or 3.3 percent of that population, and 222 female cases of HIV, or
6.1 percent of that population, in Florida's prisons. In 1995
Florida ranked second, behind New York, in the number of confirmed
AIDS cases (692), which accounts for 31.6 percent of the total HIV
cases, and 1.1 percent of the total inmate population.14
Tables 5-A through 5-D
illustrate where Florida's prisoners rank nationally in terms of the
prevalence of HIV/AIDS infection, by calendar year. (NOTE:
Testing polices for HIV vary from state to state and may account for
higher percentages of inmates diagnosed with HIV in some states.)
Table 5-A
Inmates known to be HIV+, CYs
1993-1995
(ranked by % of total population)
|
|
|
|
Total known to be positive |
HIV/AIDS cases as % of
total custody population |
|
1993 |
1994 |
1995 |
1993 |
1994 |
1995 |
|
U.S.
Total |
21,475 |
22,717 |
24,226 |
2.4 |
2.4 |
2.3 |
|
New York |
8,000 |
8,295 |
9,500 |
12.4 |
12.4 |
13.9 |
|
Connecticut |
886 |
940 |
755 |
6.6 |
6.6 |
5.1 |
|
Rhode
Island* |
89 |
113 |
126 |
3.4 |
3.8 |
4.4 |
|
Massachusetts |
394 |
388 |
409 |
3.9 |
3.4 |
3.9 |
|
New
Hampshire* |
17 |
26 |
31 |
4.4 |
3.6 |
3.7 |
|
New
Jersey |
881 |
770 |
847 |
4.4 |
3.6 |
3.7 |
|
Maryland |
769 |
774 |
724 |
3.8 |
3.7 |
3.4 |
|
Florida |
1,780 |
1,986 |
2,193 |
3.4 |
3.5 |
3.4 |
*Tests all
inmates for HIV
Source:
"HIV in Prisons and Jails, 1995," Bureau of Justice Statistics,
National Institute of Justice, August 1997
Table 5-B
Inmates known to be HIV+, CYs
1993-1995
(ranked by total number of cases)
|
|
Total known to be positive |
HIV/AIDS cases as % of
total custody population |
|
1993 |
1994 |
1995 |
1993 |
1994 |
1995 |
|
U.S.
Total |
21,475 |
22,717 |
24,226 |
2.4 |
2.4 |
2.3 |
|
New York |
8,000 |
8,295 |
9,500 |
12.4 |
12.4 |
13.9 |
|
Florida |
1,780 |
1,986 |
2,193 |
3.4 |
3.5 |
3.4 |
|
Texas |
1,212 |
1,584 |
1,890 |
1.7 |
1.6 |
1.5 |
|
California |
1,048 |
1,055 |
1,042 |
0.9 |
0.8 |
0.8 |
Source: "HIV in
Prisons and Jails, 1995," Bureau of Justice Statistics, National
Institute of Justice, August 1997
Table 5-C
Inmates Known to HIV Positive, By
Gender - 1995
|
|
Male HIV Cases |
Female HIV Cases |
|
Number |
% of Pop. |
Number |
% of Pop. |
|
Total |
20,690 |
2.3 |
2,182 |
4.0 |
|
New York |
8,678 |
13.4 |
822 |
22.7 |
|
Rhode
Island* |
105 |
3.9 |
21 |
14.5 |
|
Connecticut |
627 |
4.6 |
13 |
13.4 |
|
New
Hampshire* |
17 |
0.9 |
14 |
11.4 |
|
Massachusetts |
340 |
3.5 |
69 |
10.5 |
|
New
Jersey |
748 |
3.4 |
99 |
9.8 |
|
Florida |
1,971 |
3.3 |
222 |
6.1 |
*Tests all
inmates for HIV
Source: "HIV in Prisons and Jails, 1995," Bureau of Justice
Statistics, National Institute of Justice, August 1997
Table 5-D
Inmates with Confirmed AIDS - 1995
|
|
|
Confirmed AIDS Cases as a
percent of - |
|
# of
Confirmed AIDS Cases |
Total
HIV cases |
Custody
Population |
|
U.S.
Total |
5,099 |
21.0% |
0.5% |
|
New York |
1,182 |
12.4% |
1.7% |
|
Florida |
692 |
31.6% |
1.1% |
|
Texas |
495 |
26.2% |
0.4% |
|
California |
385 |
36.9% |
0.3% |
|
New
Jersey |
343 |
40.5% |
1.5% |
|
Maryland |
258 |
35.6% |
1.2% |
Source: "HIV in
Prisons and Jails, 1995," Bureau of Justice Statistics, National
Institute of Justice, August 1997
In 1995 Florida ranked second,
behind New York, in inmate deaths due to AIDS. Between 1989 and
1997, AIDS deaths accounted for over half (50.6 percent) of all
inmate deaths in Florida's prisons.
One national study indicates that
inmates die more quickly from AIDS than those patients who are
not incarcerated: in 1991, the median time from diagnosis to
death is 159 days for prisoners as opposed to 318 days for all
others.15
5.1.4. HIV Testing
There has been
a great debate in the correctional community over the testing of
inmates: mandatory versus voluntary. Both strategies have been
adopted by a number of state correctional systems. This past year,
South Carolina became the seventeenth state to test all inmates upon
entrance into prison, the first to adopt this practice since 1990.
Three states test all inmates in custody; three states and the
federal government test upon release.16
Both mandatory and voluntary
testing have been challenged in the courts. Those opposed to
mandatory testing questioned whether the testing violated an
inmate's right to privacy and subjected them to unlawful searches
and seizures. The courts have consistently upheld the prison's right
to mandatory testing. The courts have also denied the challenge that
failure to perform mandatory testing violates an inmate's Eighth
Amendment rights. It is important to note that no case involving
the question of HIV/AIDS in the prison setting has reached the
Supreme Court. The final word on what is required, or
prohibited, of prison officials in this area has yet to be written.17
With the advances made in recent
years in finding effective treatments for HIV, early detection
and treatment can potentially reduce the number of opportunistic
infections, and the attendant costs, and delay the diagnosis of AIDS
and deaths due to the disease.
5.1.5. Housing
Another issue
in the HIV/AIDS in prison debate is the segregation of infected
inmates. If the decision is made to segregate, which inmates
will be separated: only those with full blown AIDS, all those who
are HIV+, or those somewhere in between those two conditions?
Currently, only two states, Alabama and Mississippi, segregate all
inmates who test positive for HIV. (These two states also test all
inmates entering the system.) Most states segregate HIV/AIDS inmates
on a case-by-case basis, based on medical and/or security or other
needs.18
Segregation can have detrimental
effects on inmates.
Segregation labels the inmate, putting that individual at-risk for
discrimination and disparate treatment. It often limits the inmate's
access to work, educational and recreational programs, visitation,
and religious services. Many isolated prisoners report severe
depression, which exacerbates their medical condition. When New York
State attempted segregation of all known HIV+ inmates, the court
found that "automatic segregation to be wholly without public health
merit, often giving rise to dangerous circumstances for the
correctional community as a whole." Segregating inmates can give
those left in the general population a false sense of security about
their chances of becoming infected if they continue high-risk
behaviors.19
5.1.6. Correctional Staff
In 1988,
Congress passed the Health Omnibus Programs Extension Act (Public
Law 100-607) which included in its provisions a charge to the
Secretary of Health and Human Services and the Centers for Disease
Control and Prevention to develop and disseminate guidelines to
all public safety workers, including corrections officers,
concerning the transmission of HIV. The Bureau of Justice
Assistance AIDS Policy Project designed a training program. The
program's goal was to "change the knowledge and attitudes of
criminal justice policy makers about HIV disease and to impart the
necessary skills to develop HIV-related policies within their
respective agencies." These guidelines and programs were developed
to assist corrections departments in educating their employees about
the nature of HIV/AIDS. Early studies showed that many employees
were misinformed about the transmission of HIV. That misinformation
led to inordinate precautions being taken and discrimination against
infected inmates.20
There has been much controversy
concerning HIV/AIDS in the work place, including the issue of
confidentiality versus the duty to warn and the right to know.
Public health must be safeguarded, while at the same time protecting
the patient's rights to privacy and nondiscrimination. The courts
have frequently been called upon to decide these issues, more so
than with past infectious diseases.21
These decisions must balance the
need for disclosure against the harm done to both the individual's
privacy and the public interest. Generally, because infection
control precautions in the health care and correctional setting are
both the standard of practice and highly effective, right to know
claims are difficult to maintain. With the use of universal
infection control precautions, the risk of HIV transmission is
negligible.22
Employers, including health care
and correctional facilities, have a duty to provide a reasonably
safe workplace. The Occupational Safety and Health Administration's
blood-borne pathogen safety standard (Chapter 29, Section 1910.1030,
Code of Federal Regulations) has been challenged as too broad, but
remains the primary safety standard. In Florida, employee claims
involving occupational transmission, or fear of occupational
transmission, are covered by workers' compensation statutes,
which provide exclusive remedies for work-related claims against
employers.23
To disclose an inmate's HIV status
to unauthorized personnel may violate that person's constitutional
right to privacy; not all prison employees are authorized to
receive confidential information. Generally, legal experts agree
that the dissemination of HIV test results should be limited to
medical personnel and others who have a clear need to know.24
5.1.7. Release
The National Commission on AIDS
recommends the streamlining of early release mechanisms to allow
for the "compassionate release" of AIDS infected inmates when
their release would not compromise public safety and adequate care
is assured. The National Institute of Justice and the Centers for
Disease Control and Prevention caution that the temptation might
arise to release AIDS infected inmates early as a cost savings
measure. Their report notes that this simply shifts the burden to
another government program and often the inmate receives better care
in prison than in the community.25
5.1.8. HIV Transmission in
Prison
A great
concern of many correctional professionals is the intraprison
transmission of HIV. Several studies undertaken to date suggest
that such transmission is rare, as low as an annual incidence rate
of 0.3 percent, while another study found the rate to be as high as
21 percent. Despite such disparate findings, clearly the risk of
infection does increase with higher HIV prevalence rates among
inmates. Although sex, injection drug use, and tattooing are all
prohibited activities, they continue to occur in prisons.26
Studies on sexual activity in
prison, both consensual and nonconsensual, also vary widely in
their findings, from as low as 1 percent to as high as 90 percent.27
Research suggests that injection drug use is less frequent in
prisons than on the outside but considerably more risky because
the shortage of needles leads to increased sharing. Also, inmates
are not always aware that "sharing" includes containers, cookers,
cotton, and needles that have been used by persons not present. When
needles are not available, pieces of pens and light bulbs have been
used by inmates to inject drugs. Tattooing is a common practice
in prison, often done with whatever materials are readily
available, such as guitar strings. In tattooing, sharing the needle
or needle substitute, ink, and string used to transmit the ink may
pose risks for HIV transmission.28
5.1.9. Prevention Strategies
Universal
Precautions
In 1987 the Centers for Disease
Control and Prevention recommended that universal precautions be
consistently used for all persons regardless of their blood-borne
infection status. Under universal precautions, blood and certain
body fluids are considered potentially infectious for HIV,
hepatitis B virus, and other blood-borne pathogens and measures
should be taken to avoid exposure to these fluids. These measures
include: use of protective barriers such as gloves, gowns, masks,
and protective eyewear; preventing injuries when using needles,
scalpels, and other sharp instruments or devices; and immediately
and thoroughly washing hands and other skin surfaces that are
contaminated with blood or body fluids. Universal precautions are
now the standard in the workplace, including the correctional
setting, and have been adopted by the Occupational Safety and Health
Administration (29 CFR 1910.1030).29
HIV/AIDS Education
Prisons house high concentrations
of inmates with histories of injection and other drug use, high-risk
sexual practices, and other behaviors that may place them at
increased risk for HIV infection and who are less likely to be
reached by community-based AIDS education efforts. Also, inmate
populations are "captive audiences" available for education and
intervention programs for the length of their stays in correctional
facilities. Most prisoners will return to the community; helping
them to reduce their risk-taking behaviors benefits not only them,
but also others they may encounter in the outside world.
Education is the most common
HIV/AIDS prevention strategy employed by correctional systems.
Researchers agree that information alone is insufficient to induce
permanent changes in the often deeply ingrained or addictive
behaviors that place people at risk for HIV infection. Instead,
effective HIV prevention requires comprehensive approaches that
"address the complex contexts in which high-risk behaviors occur and
persist."30
In 1991, the National Commission
on AIDS "offered a set of recommendations relating exclusively to
corrections-based AIDS education,"31 including
mandatory participation in an AIDS education program for all inmates
upon entry into the system. (See Appendix 5.5, National Commission
on AIDS Recommendations for AIDS Prevention Programs in Correctional
Settings (1991).) These recommendations have been endorsed and
expanded on by others. The components of effective programs found
throughout the literature include:
- Programs
should be tailored to the audience, by using the appropriate
content, the appropriate presenter, and the appropriate language.
The material and the communicator must be racially and culturally
sensitive.
Generally, inmates distrust information provided by correctional
staff, particularly on controversial topics such as HIV/AIDS.
Messages regarding behavior change are more credible when they come
from a member of one's own group and reflect their values.
Peer-based programs offer a number of advantages. They can be
implemented at little cost to the correctional system; peer
educators may be more likely to speak in terms understandable to
inmates; peer educators are available for informal counseling in
various places in the prison compound, as well as conducting formal
education, counseling, and support groups; and the educators can be
available on a 24-hour basis.32
Inmates and staff have both raised issues of confidentiality in
opposition to peer programs. Some are concerned that an inmate's
HIV status may be revealed by the peer educators directly divulging
the information, or indirectly by other inmates observing
interactions between the peer educators and HIV+ inmates.33
- Programs
should emphasize risk behaviors in discussing the prevention of
HIV acquisition and transmission. The message should be one of
behavior change/modification through risk reduction. The programs
should recognize risk behaviors that occur within the facility and
provide resources that enable inmates to reduce such risks.
Injection drug use represents the primary source of heterosexual
transmission of HIV, and through pregnancy, the major route of
transmission to infants. Because injection drugs are both illegal
and addictive, educational programs that have worked addressing
other addictions do not work with injection drug users. Behavior
modification based solely on fear is not generally successful. It
has been found that injection drug users are most influenced by
programs that stress empowerment by taking charge of their lives.
According to one team of researchers, if education and prevention
efforts are to "address the nexus of injection drug use and HIV
disease," they need to contain:
- explicit
instruction/training in the cleaning of injection equipment and
other reduction strategies;
- peer
counseling relating to behavior change;
- strong
links between education and prevention and other health and
social services, such as drug abuse counseling programs; and
- the
availability of risk reduction resources.34
The
best method for achieving the necessary long-term behavior
change is through drug abuse treatment programs. Demand for
drug abuse counseling far outstrips available programs.
Also,
education programs should include clearly stated techniques to
identify, negotiate, and adopt appropriate precautions against
sexual transmission of HIV disease, such as proper condom use
and other safe sex practices.35
Researchers recommend that correctional systems should be willing
to provide the necessary resources for risk reduction, such as
condoms.36
- Female
inmates have special HIV/AIDS education needs.
Women
currently comprise the group with the fastest rate of increase in
HIV infection. The dominant risk behaviors for women are
injection drug use and heterosexual contact with an injection drug
user. The percentage of women incarcerated for drug offenses is
higher than among men. Also, women are more likely to share
equipment than men. Non-injection drug use is also closely
associated with HIV diagnosis in women. Programs for female inmates
should discuss issues of empowerment (e.g., how to deal with
male sex partners and/or violent relationships) and building
self-esteem.37
- Programs
should contain an evaluation component.38
Without an evaluation component of any educational program in place,
it is hard to determine if the program is reaching the inmates
that need to be tested, if the information being given is
understood and learned, and if resources dedicated to HIV/AIDS
education are being optimally used.
Other Strategies
The more controversial strategies
for HIV prevention include the distribution of condoms and sterile
injection equipment. These approaches are fraught with problems.
Since sex and drugs are prohibited in the correctional setting,
supplying condoms and sterile needles or bleach to inmates might
convey the message that these behaviors are condoned. Sex and drugs
are present in prisons, however, and failing to acknowledge the
situation complicates a dangerous health care problem. Many
health professionals advocate treating the conditions inside prison
with the public health model and effectively dealing with HIV by
distributing condoms. Correctional officials fear that allowing
condoms would undermine security and adherence to regulation.
Condoms could be used as weapons or to conceal drugs or other
contraband.39
Currently six corrections
systems within the
United States (Mississippi and Vermont prison and the San Francisco,
Philadelphia, New York City and Washington, D.C., jail systems) and
the Canadian federal prison system make condoms available to
inmates. Vermont, for example, makes condoms available while
adhering to a prohibition on sex. San Francisco and Washington jail
systems and the Canadian federal system also make dental dams
available for women. Systems that do allow condom availability have
not seen an increase in security violations as a result of their
use. It is noteworthy that since the late 1980s when these policies
were adopted, no system has reversed the policy of making condoms
available to inmates.40
Bleach and needles are present in
the prison environment for other uses. The inability to sterilize
the equipment increases the risk of transmitting infection. While
many correctional systems provide information on safer injection
practices in their education and counseling, three systems --
San Francisco and Harris County (Houston) jail systems and the
Canadian federal system -- provide bleach, but no system
distributes needles. (A female facility in Switzerland has
started a pilot needle exchange program.) Research has shown that
bleach is only effective as a disinfectant when correct procedures
are followed carefully. Therefore, bleach is only recommended "when
no other safer options are available."41
5.1.10. Costs of Testing for
and Treating HIV/AIDS
As indicated
in Table 5-E, HIV/AIDS now accounts for 7.8 percent of the DC's
Office of Health Services' (OHS) budget.
Table 5-E
Cost of HIV/AIDS as Percentage of
Total of
Office of Health Services Budget
FY 1994-95 - FY 1997-98
|
|
OHS |
HIV/AIDS |
|
FY
94-95 |
Total
Expenditures |
$176,151,934 |
$8,127,836 |
|
% of
Budget |
100.0% |
4.6% |
|
FY
95-96 |
Total
Expenditures |
$194,406,876 |
$7,759,530 |
|
% of
Budget |
100.0% |
4.0% |
|
FY
96-97 |
Total
Expenditures |
$206,158,679 |
$10,774,183 |
|
% of
Budget |
100.0% |
5.2% |
|
FY
97-98 |
Total
Expenditures |
$220,402,224 |
$17,104,188 |
|
% of
Budget |
100.0% |
7.8% |
Source: Office of
Health Services, Florida Department of Corrections
The OHS was asked to provide the
costs of testing for and treating HIV/AIDS and an explanation of
how those costs are estimated. The Commission received the following
explanation:
|
|
OHS has
tracked HIV/AIDS costs as a separate budget object over the past
5-6 years in order to establish yearly per diem baselines. These
historical costs serve as the forecasting basis for the next
year's estimated treatment costs. Once the basis is determined,
the projected inmate admission population and corresponding
extrapolation for the newly identified HIV/AIDS infected inmates
is incorporated into the estimate. Improvement in treatment
regimens are considered.42 |
|
According to the DC's Legislative
Budget Requests (LBRs) for FY 1997-98 - FY 1999-00, to estimate the
necessary funding for AIDS, the department multiplies the average
daily population by the current prevalence rate of HIV/AIDS cases,
then multiples the projected number of cases by the projected cost
of treatment per case (the current cost per case X the average rate
of increase in drug and medical care costs). (See Tables 5-F through
5-H.) The Legislative Budget Requests noted that
|
|
expenditures for the treatment of AIDS/HIV will continue to
increase not only as the population increases but also as a
result of stricter sentencing guidelines
as inmates suffering from the disease are now remaining in the
system through the sicker, more costly, stages of the illness.
The new Centers for Disease Control and Prevention treatment
guidelines requiring the use of protease inhibitors and viral
load testing for HIV/AIDS cases will further increase costs.43 |
|
Table 5-F
Florida Department of Corrections
Estimated Cost of HIV/AIDS Treatment
LBRs FY 1997-98 - FY 1999-00
|
LBR for |
FY 1997-98 |
|
LBR for |
FY 1998-99 |
|
1995-96
actual AIDS expenditure |
$7,759,530 |
|
1996-97
actual AIDS expenditure |
$10,101,406 |
|
1995-96
average cost per case |
$2,663 |
|
1996-97
average cost per case |
$4,727 |
|
X 3.6%
increase |
$2,858 |
|
X 2.9%
increase |
$5,005 |
|
1997-98
average daily population |
69,913 |
|
1998-99
average daily population |
67,193 |
|
X
prevalence rate of HIV/AIDS |
X4.6% |
|
X
prevalence rate of HIV/AIDS |
X3.4% |
|
1997-98
projected HIV/AIDS cases |
3,216 |
|
1998-99
projected HIV/AIDS cases |
2,285 |
|
X 1997-98
projected cost per case |
X $2,858 |
|
X 1998-99
projected cost per case |
X $5,005 |
|
1997-98
projected AIDS expenditures |
$9,191,328 |
|
1998-99
projected AIDS expenditures |
$11,436,425 |
|
less
1996-97 appropriation |
-6,300,000 |
|
less
1997-98 appropriation |
-6,300,000 |
|
1997-98
additional funding request |
$2,891,328 |
|
1998-99
additional funding request |
$5,136,425 |
|
|
|
|
|
|
|
LBR for |
FY 1999-00 |
|
|
1997-98
projected HIV/AIDS expenditures |
$17,200,000 |
|
1997-98
average cost per case |
$9,052 |
|
X 2.9%
increase |
$9,585 |
|
1999-00
average daily population |
66,941 |
< |